Recent developments in delivery of nucleic acid-based antiviral agents

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 1995-2006

  Christopher, M E ^a   Wong, Jonathan P ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Immunopotentiating reconstituted influenza virosomes; Liposomes; Nanoparticles; Viral vectors

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHOLESTEROL; CHOLESTEROL HYDROGEN SUCCINATE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA VACCINE; LIPOFECTAMINE; LIPOFECTIN; LIPOPLEX; LIPOSOME; MACROGOL; MESSENGER RNA; NANOPARTICLE; NUCLEASE; NUCLEIC ACID; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PHOSPHATIDYLCHOLINE; PLASMID DNA; POLYGLACTIN; POLYSORBATE 80; VIRUS VECTOR;

AEROSOL; ANTIVIRAL ACTIVITY; BACULOVIRUS; DNA VIRUS; DRUG EFFICACY; DRUG STABILITY; ENCAPSULATION; ENZYME DEGRADATION; GENE CONTROL; GENE FUNCTION; GENETIC TRANSFECTION; GENOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RNA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DNA VIRUSES; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOSOMES; NANOSTRUCTURES; RNA VIRUSES;

EID: 33744727387     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442146     Document Type: Review

References (125)

1. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent application. Nat Rev Drug Discov 2002; 1: 503-14.
2. Gorman J. Delivering the goods. Gene therapy without the virus. Sci News 2003; 163: 43.
3. Santiago FS, Khachigian LM. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J Mol Med 2001; 79: 695-706.
4. Audouy SAL, de Leij LFMH, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002; 19: 1599-1605.
5. Pelisek J, Engelmann MG, Golda A, Fuchs A, Armeanu S, Shimizu M, et al. Optimization of nonviral transfection: variables influencing liposome-mediated gene transfer in proliferating vs. quiescent cells in culture and in vivo using a porcine restenosis model. J Mol Med 2002; 80: 724-36.
6. Anchordoquy TJ, Carpenter JF, Kroll DJ. Maintenance of transfection rates and physical characterization of lipid/DNA complexes after freeze-drying and rehydration. Arch Biochem Biophys 1997; 348: 199-206.
7. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Rel 2004; 94: 1-14.
8. Cryz Jr S, Davis SS, Gregoriadis G, Grimaud J-A, Kourilsky P, Selkirk ME, et al. European Commission COST/STD initiative. Report of the expert panel. Vaccine delivery systems. Vaccine 1996; 7: 665-90.
9. Kersten GFA, Crommelin DJA. Liposomes and ISCOMs. Vaccine 2003; 21: 915-20.
10. Sha Z, Vincent MJ, Compans RW. Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. Immunobiology 1999; 200: 21-30.
11. Wong JP, Zabielski MA, Schmaltz FL, Brownlee GG, Bussey LA, Marshall K, et al. DNA vaccination against respiratory influenza virus infection. Vaccine 2001; 19: 2461-7.
12. Wong JP, Nagata LP, Dale RMK. Liposome-encapsulated nucleic acid-based drugs and vaccines as novel antiviral agents. Recent Devel Antiviral Res 2001; 1: 175-91.
13. Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002; 20: 3342-54.
14. Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Wadhwa MS, et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum Gene Ther 1998; 9: 2083-99.
15. Almofti MR, Harashima H, Shinihara Y, Almofti A, Baba. Y, Kiwada H. Cationic liposome-mediated gene delivery: Biophysical study and mechanism of internalisation. Arch Biochem Biophys 2002; 410: 246-53.
16. Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum Gene Ther 1997; 8: 1585-94.
17. Simoes S, Slepushkin V, Duzgunes N, Pedroso de Lima MC. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 2001; 1515: 23-7.
18. Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acts, 2000, 1475: 125-32.
19. Jiao X, Wang RY, Feng Z, Alter HJ, Shih JW. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 2003; 37: 452-60.
20. Parker SE, Ducharme S, Norman J, Wheeler CJ. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997; 8: 393-401.
21. Dass CR. Inummostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol 2002; 128: 177-81.
22. Loisel S, Le Gall C, Doucet L, Ferec C, Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001: 12: 685-96.
23. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12: 751-61.
24. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001; 19: 3301-10.
25. Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Düzgünes N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1998; 1372: 55-68.
26. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharm Rev 2000; 52: 325-47.
27. Abe T, Mizuta T, Hatta T, Miyano-Kurosaki N, Fujiwara M, Takai K, et al. Antisense therapy of influenza. Eur J Pharm Sci 2001; 13: 61-9.
28. Saravolac EG, Sun LQ, Cairns MJ, Wong JP. Nucleic acid-based drugs as antiviral agents. Recent Devel Antiviral Res 2001; 1: 117-41.
29. Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 2002; 121: 289-99.
30. Saravolac EG, Ludkovski O, Skirrow R, Ossanlou M, Zhang YP, Giesbrecht C, et al. Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity. J Drug Target 2000; 7: 423-37.
31. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, et al. Efficient encapsulation of antisense oligotrucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biopbys Acta 2001; 1510: 152-66.
32. Yu R, Geary RS, Leeds JM, Watanabe T, Fitchett JR, Matson JE, et al. Pharmokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulate in stealth liposomes. Pharm Res 1999; 16: 1309-15.
33. Tseng Y-L, Liu J-J, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides Penetratin and Tat: A kinetic and efficacy study. Mol Pharmacol 2002, 62: 864-72.
34. Hong K, Zheng W, Baker A, Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett 1997; 400: 233-37.
35. Ponnappa BC, Dey I, Tu G-C, Zhou F, Ami M, Cao Q-N, et al. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats. J Pharmacol Exp Ther 2001; 297: 1129-36.
36. Skalko-Basnet N, Tohda M, Watanabe H. Uptake of liposomally entrapped fluorescent antisense oligonucleotides in NG108-15 cells: conventional versus pH-sensitive. Biol Pharm Bull 2002; 25: 1583-7.
37. Sudimack JJ, Guo W, Tjarksw W, Lee RJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta 2002; 1564: 31-7.
38. Chang JS, Choi MJ, Cheong HS, Kim K. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes Vaccine 2001; 19: 3608-14.
39. Kono K, Torikoshi Y, Mitsutomi M, Hoh T, Emi N, Yanagie H, et al. Novel gene delivery systems: complexes of fasigenic polymer-modified liposomes and lipoplexes. Gene Ther 2001; 8:5-12.
40. Duncan JE, Whitsett JA, Horowitz AD. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum Gene Ther 1997; 8: 431-8.
41. Tsan M-F, Tsan GL, White JE. Surfactant inhibits cationic liposome-mediated gene transfer. Hum Gene Ther 1997; 8: 817-25.
42. Eastman SJ, Lukason MJ, Tousignant JD, Murray H, Lané MD, St. George JA, et al. A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther 1997; 8: 765-73.
43. Eastman SJ, Tousignant JD, Lukason MJ, Murray H, Siegel CS, Constantino P, el al. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum Gene Ther 1997: 8: 313-22.
44. Eastman SJ, Tousignant JD, Lukason MJ, Chu Q, Cheng SH, Scheule RK. Aerosolization of cationic lipid:pDNA complexes - in vitro optimization of nebulizer parameters for human clinical studies. Hum Gene Ther 1998; 9: 43-52.
45. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. Biochim Biophys Acta 2002; 1564: 343-8.
46. Gu J-L, Nadler J, Rossi J. Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Mol Cell Biol 1997; 172: 47-57.
47. Lee ER, Marshall J, Siegel CS, Jiang C, Yew NS, Nichols MR, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996; 7: 1701-17.
48. Kitajima I, Hanye N, Soejima Y, Hirano R, Arahira S, Yamaoka S, et al. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Applications for ribozymes that target human T-cell leukemia virus type I tat/rex mRNA. J Biol Chem 1997; 272: 27099-106.
49. Zhang Y, Boado RJ, Pardridge WM. Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med 2003; 5: 157-63.
50. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, et al. Epidermal growth factor receptor (EGFR)-targeted immumoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003; 63: 3154-61.
51. Xu L, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002, 1: 337-46.
52. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, et al. Targeting of the photocytotoxic compound AIPcS4 to Hela cells by transferring conjugated PEG-liposomes. Int J Cancer 2002; 101: 78-85.
53. Allen TM, Sapra P, Moase E, Moreira J, Iden D. Adventures in targeting. J Liposome Res 2002; 12: 5-12.
54. Janssen AP, Schiffelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, et al. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm 2003; 254: 55-8.
55. Zhou W, Yuan X, Wilson A, Yang, L, Mokotoff M, Pitt B, et al. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem 2002; 13: 1220-5.
56. Tomita N, Morishita R, Yamamoto K, Higaki J, Dzau VJ, Ogihara T, et al. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med 2002; 4: 527-35.
57. Sato A, Kawakami S, Yamada M, Yamashita F, Hashida M. Enhanced gene transfection in macrophages using mannosylated cationic liposome-polyethylenimine-plasmid DNA complexes. J Drug Target 2001; 9: 201-7.
58. Opanasopit P, Higuchi Y, Kawakami S, Yamashita F, Nishikawa M, Hashida. M. Involvement of serum mannan binding proteins and mannose receptors in uptake of mannosylated liposomes by macrophages. Biochim Biophys Acta 2001; 1511: 13445.
59. Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, Hashida M. Biodistribution characteristics of mannosylated, facosylated, and galactosylated liposomes in mice. Biochim Biophys Acta 2000; 1524: 258-65.
60. Nag A,, Ghosh PC. Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver. J Drug Target 1999; 6: 427-38.
61. Torchilin VP. Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv Drug Deliv Rev 2005; 57: 95-109.
62. Freimark BD, Blezinger HP, Florack VJ, Nordstrom JL, Long SD, Deshpande DS, et al. Cationic; lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 1998; 160: 4580-6.
63. Elouahabi A, Flamand V, Ozkan S, Paulart F, Vandenbranden M, Goldman M, et al. Free cationic liposomes inhibit the inflammatory response to cationic lipid-DNA comples injected intravenously and enhance its transfection efficiency. Mol Ther 2003; 7: 81-8.
64. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Hélène C, et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 1994; 91: 10460-4.
65. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm Res 2000; 17: 707-14.
66. Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice J Pharmacol Exp Ther 1997; 280: 232-7.
67. Wang D, Robinson DR, Kwon GS, Samuel J. Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release 1999; 4: 9-18.
68. Kende M, Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 2002; 20: 1681-91.
69. Fenart L, Casanova A, Duhem BC, Slupek S, Cecchelli R, Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999; 291: 1017-22.
70. Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE, et al. Intranasal immunization with mumps virus DNA vaccine delivery by influenza virosomes elicits mucosal and systemic immunity. Virology 2000; 277: 111-8.
71. Glück R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 1999; 17: 1782-7.
72. Hunziker IP, Grabscheid B, Zurbriggen R, Glück R, Pichler WJ, Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int Immunol 2002; 16: 615-6.
73. Hug P, Sleight RG. Fusogenic virosomes prepared by partitioning of vesicular stomatitis virus G protein into preformed vesicles. J Biol Chem 1994; 269: 4050-6.
74. Ramani K, Hassan Q, Venkaiah B, Hasnain SE, Sarkar DP. Site-specific gene delivery in vivo through engineered Sendai viral envelopes. Proc Natl Acad Sci USA 1998; 29: 11886-90.
75. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-604.
76. Ring CJA. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.
77. Huard J, Akkaraju G, Watkins SC, Pike-Cavalcoli M, Glorioso J. LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. Hum Gene Ther 1997; 8: 439-52.
78. Kaner RJ, Worgall S, Leopold PL, Stolze E, Milano E, Hidaka C, et al. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of gene expression of the coxsackie/adenovirus receptor. Am J Resp Cell Mol Biol 1999; 20: 361-70.
79. Skog J, Mei Y-F, Wadell G. Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumor origin. J Gen Virol 2002; 83: 1299-309.
80. von Seggern DJ, Kehler J, Endo RI, Nemerow GR. Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J Gen Virol 1998; 79: 1461-8.
81. Mittal SK, Prevec L, Graham FL, Babiuk LA. Development of a bovine adenovirus type 3-based expression vector. J Gen Virol 1995; 76: 93-102.
82. Varnavski AN, Zhang Y, Schnell M, Tazelaar J, Louboutin JP, Yu QC, et al. Pre-existing immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 2002; 76: 5711-9.
83. Flanagan B, Pringle CR, Leppard KN. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J Gen Virol 1997; 78: 991-7.
84. Macejak DG, Lin H, Webb S, Chase J, Jensen K, Jarvis TC, et al. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle prolifieration and neointima formation in vivo. J Virol 1999; 73: 7745-51.
85. Shering AF, Bain D, Stewart K, Epstein AL, Castri MG, Wilkinson GWG, et al. Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gen Virol 1997; 78: 445-59.
86. Bruce CB, Akrigg A, Sharpe SA, Hanke T, Wilkinson GWG, Cranage MP. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol 1999; 80: 2621-8.
87. Sollerbrant K, Elmén J, Wahlestedt C, Acker J, Leblois-Prehaud H, Latta-Mahieu M, et al. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J Gen Virol 2001; 82: 2051-60.
88. Fooks AR, Jeevarajah D, Lee J, Warnes A, Niewiesk S, ter Meulen V, et al. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J Gen Virol 1998; 79: 1027-31.
89. Ogasawara Y, Mizukami H, Urabe M, Kume A, Kanegae Y, Saito I, et al. Highly regulated expression of adeno-associated virus large Rep proteins in stable 293 cell lines using the Cre/loxP switching system. J Gen Virol 1999; 80: 2477-80.
90. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079-88.
91. Chen Y, Luk KD, Cheung KM, Xu R, Lin MC, Lu WW, et al. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Ther 2003; 10: 1345-53.
92. Bainbridge JW, Mistry A, Schlichtenbrede FC, Smith A, Broderick C, De Alwis M, et al. Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina. Gene Ther 2003; 10: 1336-44.
93. Sarkar R, Xiao W, Kazazian HH. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost 2003; 1: 220-6.
94. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
95. Shoji I, Aizaki H, Tani H, Ishii K, Chiba T, Saito I, et al. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors. J Gen Virol 1997; 78: 2657-64.
96. Lagunoff M, Randall G, Roizman B. Phenotypic properties of herpes simplex virus 1 containing a derepressed open reading frame P gene. J Virol 1996; 70: 1810-7.
97. Hanke T, Blanchard TJ, Schneider J, Oggs GS, Tan R, Becker M, et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 1998, 79: 83-90.
98. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost regimen. J Virol 1999; 73: 7524-32.
99. International AIDS Vaccine Initiative (2003_Midyear_complete_final.pdf) http://www.iavi.org.
100. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4: 397-402.
101. Lai Z, Brady RO. Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. J Neurosci Res 2002; 67: 363-71.
102. Mautino MR, Morgan RA. Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS 2002; 16: 11-26.
103. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z, et al. Lentiviral vectors containing the hurnan immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-22.
104. Morris KV, Rossi JJ. Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr HIV Res 2004; 2: 186-91.
105. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med 2004; 6: 597-602.
106. Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991; 65: 5531-4.
107. Kobayashi H, Takemura Y, Wang F-S, Oka T, Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: Screening for effective target sites. Int J Cancer 1999; 81: 944-50.
108. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol 2002; 2: 15-20.
109. Hanke T, Barnfield C, Wee EG-T, Ågren L, Samuel RV, Larke N, et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 2003; 84: 361-8.
110. Vignuzzi M, Gerbaud S, van der Werf S, Escriou N. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J Gen Virol 2001; 82: 1737-47.
111. Varnavski AN, Young PR, Khromykh AA. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 2000; 74: 4394-403.
112. Lee JS, Dyas BK, Nystrom SS, Lind CM, Smith JF, Ulrich RG. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J Infect Dis 2002; 185: 1192-6.
113. Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J Gen Virol 2002; 83: 2635-62.
114. Sallenave JM, Xing Z, Simpson AJ, Graham FL, Gauldie J. Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. Gene Ther 1998; 5: 352-60.
115. Medina MF, Joshi S. RNA-polymerase III-driven expression cassettes in human gene therapy. Curr Opin Mol Ther 1999; 1: 580-94.
116. Kuwabara T, Warashina M, Koseki S, Sano M, Ohkawa J, Nakayama K, et al. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucleic Acids Res 2001; 29: 2780-8.
117. Walker K, Xie Y, Li Y, Zhu Q, Zu W, Wagner TE, et al. Cytoplasmic expression of ribozyme in zebrafish using T7 autogene system. Curr Issues Mol Biol 2001; 3: 1-6.
118. Block A, Puls F, Muller J, Milasinovic D, Ingelmann D, Schafer P, et al. Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system. J Gene Med 2003; 5: 190-200.
119. Smaglik P. Tighter watch urged on adenoviral vectors. Nature 1999; 402: 707.
120. Check E. Cancer risk prompts US to curb gene therapy. Nature 2003; 422: 7.
121. Chu Q, St. George JA, Lukason M, Cheng SH, Scheule RK, Eastman SJ. EGTA enhancement of adenovirus-mediated gene transfer to mouse tracheal epithelium in vivo. Hum Gene Ther 2001; 12: 455-67.
122. Cech T, Bass B. Biological catalysis by RNA. Annu Rev Biochem 1986; 55: 599-629.
123. Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 2004; 10(26): 3263-74.
124. Shoji Y, Nakashima H. Current status of delivery systems to improve target efficacy of oligonucleotides. Curr Pharm Des 2004; 10(7): 785-96.
125. Xodo LE, Cogoi S, Rapozzi V. Anti-gene strategies to down-regulate gene expression in mammalian cells. Curr Pharm Des 2004; 10(7): 805-19.